← Back to Search

NMDA Receptor Antagonist

Ketamine for Cardiac Arrest (KetCat Trial)

N/A
Recruiting
Research Sponsored by Fraser Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 months.
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether ketamine, a common sedative, can help improve brain function in people who have had a cardiac arrest. The goal is to see if ketamine can reduce the damage caused by lack of oxygen to the brain during cardiac arrest. Ketamine has been studied for its potential to protect the brain and improve outcomes after cardiac arrest.

Eligible Conditions
  • Neurologic Deficits
  • Neurologic Symptoms
  • Cardiac Arrest
  • Ketamine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 6 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility Data

Side effects data

From 2020 Phase 4 trial • 75 Patients • NCT03156504
1%
Lightheadedness with low blood pressure
1%
Pump Malfunction
1%
PTSD
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ketamine ArmExperimental Treatment1 Intervention
Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
Group II: Control ArmActive Control1 Intervention
Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine Hydrochloride
2018
Completed Phase 4
~1900

Find a Location

Who is running the clinical trial?

Fraser HealthLead Sponsor
47 Previous Clinical Trials
707,588 Total Patients Enrolled

Media Library

Ketamine Hydrochloride (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04360070 — N/A
Neurologic Deficits Research Study Groups: Ketamine Arm, Control Arm
Neurologic Deficits Clinical Trial 2023: Ketamine Hydrochloride Highlights & Side Effects. Trial Name: NCT04360070 — N/A
Ketamine Hydrochloride (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04360070 — N/A
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top